Susceptibility Profile to Common Antimicrobials Used for Eradication of<i>Helicobacter pylori</i>Infection in Mexico by Agar Dilution Method

Morales-Espinosa, Rosario; González-Valencia, Gerardo; Delgado, G.; Navarro, Armando; García, Virgilio Bocanegra; Cravioto, Alejandro

doi:10.1179/joc.2007.19.1.108

Cited by 3 publications

(4 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This result is lower than that reported in 2001 by Torres et al,(24%) and higher than reported in other studies in the Mexican population where the frequency of resistance varies between 4% and 8% in patients with chronic gastritis and peptic ulcer (Ayala et al, 2011;. Chihu et al, 2005;Garza-González et al, 2002;Morales-Espinosa et al, 2007). In Latin America the prevalence of clarithromycin resistance varies between populations and countries.…”

Section: Accepted Manuscriptcontrasting

confidence: 81%

“…Clarithromycin is included in the standard triple therapy. To our knowledge, only five studies report the prevalence of clarithromycin resistance in Mexican population (Ayala et al, 2011;Chihu et al, 2005;Garza-González et al, 2002;Morales-Espinosa et al, 2007;Torres et al, 2001) and in four of them patients from Mexico city were studied. The frequency of phenotypic clarithromycin resistance in H. pylori strains isolated from patients with…”

Section: Concordance Between Phenotypic and Genotypic Clarithromycin mentioning

confidence: 99%

“…The prevalence of clarithromycin resistance in H. pylori varies for each area; in America it is 29.3%, 11.1% in Europe, 18.9% in Asia and 92.3% in Africa (Papastergiou et al, 2014;Wu et al, 2012). In Mexico, the frequency of resistance to this antibiotic ranges from 4% to 25% and changes with the geographic area (Ayala et al, 2011;Chihu et al, 2005;Garza-González et al, 2002;Morales-Espinosa et al, 2007;Torres et al, 2001). Point mutations in the coding region peptidyltransferase in domain V of the 23S rRNA of H. pylori are responsible for clarithromycin resistance, by modifying the target site.…”

Section: Introductionmentioning

confidence: 97%

“…they have covered a limited geographical area and none in population of the south region (Ayala et al, 2011;Chihu et al, 2005;Garza-González et al, 2002;Morales-Espinosa et al, 2007;Torres et al, 2001). Knowledge of clarithromycin susceptibility in H. pylori locally, is useful for selecting appropriate treatment.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis

Alarcón‐Millán

Fernández‐Tilapa

Cortés-Malagón

et al. 2016

Infection, Genetics and Evolution

View full text Add to dashboard Cite

In developing countries, clarithromycin resistance and frequency of re-infection are factors that contribute to high prevalence of Helicobacter pylori infection. The aim of this research was determine the prevalence of clarithromycin resistance and its relation with A2142G, A2142C and A2143G mutations in the domain V of the 23S rRNA gene of H. pylori isolates in patients from Southern Mexico with chronic gastritis. Another purpose of this work was to study the prevalence of virulent genotypes and distribution of resistant strains according to the vacA/cagA/babA2 H. pylori genotypes. One hundred forty-four patients with chronic gastritis were studied. Forty-five H. pylori strains were isolated and clarithromycin susceptibility was determined by the disk-diffusion method. The 82.2% of the strains had the combination of alleles vacA s1 m1 and the cagA gene was detected in 77.8% and 40% of the strains were babA2 positive. The vacA s1 m1 genotype was detected more frequently in cagA(+) strains, vacA s1m1/cagA(+)/babA2(-) genotype was more frequent than vacA s1m1/cagA(+)/babA2(+), 37.8% and 33.3%, respectively. Eight strains were clarithromycin resistant, in three of these, point mutations were identified, but only in one strain the A2143G mutation associated with clarithromycin resistance was found. Other point mutations (A1821G, G1826A, T1830C, A2089G, T1600C, C1601T, C1602T, T1610C, A1611C and T1633G) that have not been associated with clarithromycin resistance were identified. The highest proportion of resistant strains was vacA s1m1/cagA(+) (62.5%). In patients from southern Mexico with chronic gastritis, the prevalence of clarithromycin resistance is within internationally accepted range (17.8%) and allows continued use of triple therapy for H. pylori eradication. However, it is necessary to monitor the evolution of clarithromycin resistance in this area. The largest proportion of resistant H. pylori strains is not harboring the A2142G, A2142C and A2143G mutations in the 23S rRNA gene (87.5%). The vacA s1m1/cagA(+) genotype was the most prevalent and among clarithromycin-resistant strains, this was the predominant.

show abstract

Section: Accepted Manuscriptcontrasting

confidence: 81%

Section: Concordance Between Phenotypic and Genotypic Clarithromycin mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 97%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Clarithromycin resistance and prevalence of Helicobacter pylori virulent genotypes in patients from Southern México with chronic gastritis

Alarcón‐Millán

Fernández‐Tilapa

Cortés-Malagón

et al. 2016

Infection, Genetics and Evolution

View full text Add to dashboard Cite

show abstract

IV consenso mexicano sobre Helicobacter pylori

Bosques-Padilla

Remes-Troche

González-Huezo

et al. 2018

Revista de Gastroenterología de México

View full text Add to dashboard Cite

Important advances have been made since the last Mexican consensus on the diagnosis and treatment of Helicobacter pylori (H. pylori) infection was published in 2007. Therefore, the Asociación Mexicana de Gastroenterología summoned 20 experts to produce "The Fourth Mexican Consensus on Helicobacter pylori". From February to June 2017, 4 working groups were organized, a literature review was performed, and 3 voting rounds were carried out, resulting in the formulation of 32 statements for discussion and consensus. From the ensuing recommendations, it was striking that Mexico is a country with an intermediate-to-low risk for gastric cancer, despite having a high prevalence of H. pylori infection. It was also corroborated that peptic ulcer disease, premalignant lesions, and histories of gastric cancer and mucosa-associated lymphoid tissue lymphoma should be considered clear indications for eradication. The relation of H. pylori to dyspeptic symptoms continues to be controversial. Eradication triple therapy with amoxicillin, clarithromycin, and a proton pump inhibitor should no longer be considered first-line treatment, with the following 2 options proposed to take its place: quadruple therapy with bismuth (proton pump inhibitor, bismuth subcitrate, tetracycline, and metronidazole) and quadruple therapy without bismuth (proton pump inhibitor, amoxicillin, clarithromycin, and metronidazole). The need for antimicrobial sensitivity testing when 2 eradication treatments have failed was also established. Finally, the promotion of educational campaigns on the diagnosis and treatment of H. pylori for both primary care physicians and the general population were proposed.

show abstract